Tocilizumab
‘Recovery Trial’ finds anti-arthritis drug reduces severe COVID-19 mortality

The trial found that Baricitinib reduces the mortality of hospitalized patients by 13%. Baricitinib inhibits the enzymes of a specific family of enzyme called the Janus Kinase (JAK) family

COVID-19 treatment: SOLIDARITY trial is restarting with 3 drugs this time

The drug candidates for repurposing are imatinib, a cancer drug; infliximab, an antibody; and artesunate, an anti-malarial drug. The tests seek to explore possible drugs that can be repurposed to treat severely affected COVID-19 patients

    × To Subscribe